Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors

Summary

The goal of this multicenter prospective single-arm phase I/II study is to study the safety and efficacy stereotactic body radiotherapy (SBRT) combined with Cadonilimab for advanced refractory malignant solid tumors. The main questions it aims to answer are: * How safe is this regimen of SBRT combined with Cadonilimab for advanced refractory malignant solid tumors? * How effective is this regimen of SBRT combined with Cadonilimab for advanced refractory malignant solid tumors? Participants will receive SBRT combined with Cadonilimab until disease progression or intolerable toxicities or death.

Timeline

Start

2023-06-21

Primary completion

2024-06-21

Completion

2025-06-21

Publications

• Xiao Y, Wang Y, Li J, Cheng C, Song C, Wang X, Tao L, Zhuang H. Stereotactic body radiotherapy plus cadonilimab (PD-1/CTLA-4 bispecific antibody) as third-line or beyond therapy for refractory solid tumors: A phase 1b study. Cancer Commun (Lond). 2025 Oct;45(10):1235-1246. doi: 10.1002/cac2.70051. Epub 2025 Jul 22.

Drugs

Indications